Document is current
Any future updates will be listed below
-
Authors
Bhosle, Amrisha https://orcid.org/0000-0001-8669-4979
Bae, Sena
Zhang, Yancong https://orcid.org/0000-0002-2768-2975
Chun, Eunyoung https://orcid.org/0000-0001-7444-7559
Avila-Pacheco, Julian https://orcid.org/0000-0001-9388-3946
Geistlinger, Ludwig
Pishchany, Gleb
Glickman, Jonathan N https://orcid.org/0000-0003-0910-2655
Michaud, Monia
Waldron, Levi https://orcid.org/0000-0003-2725-0694
Clish, Clary B https://orcid.org/0000-0001-8259-9245
Xavier, Ramnik J
Vlamakis, Hera
Franzosa, Eric A https://orcid.org/0000-0002-8798-7068
Garrett, Wendy S https://orcid.org/0000-0002-5092-0150
Huttenhower, Curtis https://orcid.org/0000-0002-1110-0096
-
Funding
Funding for this research was provided by:
HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R24DK110499)
- License Information
-
More Information
Article History
Received: 20 September 2023
Revised: 13 February 2024
Accepted: 15 February 2024
First Online: 11 March 2024
Disclosure and competing interests statement
: CH is on the scientific advisory board of ZOE, Seres Therapeutics, and Empress Therapeutics. WSG is on the scientific advisory board of Freya Biosciences, Sail Biomedicines, Scipher Medicine, and Empress Therapeutics. The laboratory of WSG receives funding from Merck and Astellas, unrelated to current work. RJX is a member of the scientific advisory board of Nestle and Senda Biosciences.
